OncLive TV

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.

Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

Alexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.

Javier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.